Oestrogen's Role in Prostate Cancer

QUIET BIOLOGY FRAMEWORK | Scientific Support Paper No. 10

Finley Proudfoot | Quiet Biology Framework | March 2026

Structured Abstract

Background	Prostate cancer is framed almost exclusively as an androgen-dependent disease, and clinical management reflects this framing. Oestrogen’s role has been acknowledged at the level of receptor biology, the opposing functions of ERα and ERβ are recognised, but has not been integrated into a coherent mechanistic account of disease initiation, progression, and therapy resistance. This paper argues that oestrogen operates through at least four distinct, interconnected mechanisms in prostate cancer that have been individually described in the literature but never assembled into a unified framework.
Methods	Narrative synthesis across four mechanistic domains: (1) the ERα/ERβ receptor balance and its remodelling during disease progression; (2) intratumoral aromatase and locally generated oestrogen, including its concentration in the cancer stem cell fraction; (3) the estrobolome, the gut microbial apparatus governing oestrogen recirculation, and its relevance to prostate cancer; (4) xenoestrogen loading and its interactions with androgen receptor signalling. The TMPRSS2:ERG gene fusion, present in approximately 50% of prostate cancers, is examined as a specific intersection point between oestrogen signalling and the most common molecular subtype of the disease.
Results	ERα upregulation and progressive ERβ loss are well-replicated findings across disease stages, with ERβ loss mechanistically linked to EMT permissiveness, HIF-1α stabilisation, and Gleason grade. Intratumoral aromatase switches from stromal-only expression in benign tissue to epithelial expression in malignancy, and is concentrated in CD44+ cancer stem cells in CRPC, where it drives ERα-dependent MMP12 expression and invasion. The estrobolome mechanism, β-glucuronidase-mediated deconjugation and reabsorption of oestrogens, is well-characterised in breast cancer and acknowledged but underexamined in prostate cancer. Xenoestrogens including BPA activate AR at environmentally relevant doses and stimulate AR splice variants, connecting the xenoestrogen literature to the established CRPC resistance mechanism. The TMPRSS2:ERG fusion, found in approximately half of prostate cancers, is regulated by both androgen and oestrogen signalling, ERα agonism increases fusion expression, ERβ agonism decreases it, making oestrogen a co-driver of the most prevalent molecular subtype of the disease.
Conclusions	Oestrogen is not a bystander hormone in prostate cancer. It operates through at least four mechanisms that contribute to initiation, progression, EMT, invasion, castration resistance, and the expression of the disease’s most common gene fusion. The clinical and therapeutic implications of this framework have been substantially underexplored. This paper argues that oestrogen deserves a structural place in how prostate cancer is understood and managed, not as an afterthought to the androgen axis, but as a parallel hormone system that interacts with it at multiple critical junctures.

01Introduction

Prostate cancer carries the distinction of being the cancer most thoroughly defined by its relationship to a single hormone. Androgen deprivation therapy has been a cornerstone of management for more than eight decades, and the molecular biology of the disease has largely been organised around the androgen receptor. When that receptor adapts, through amplification, mutation, splice variation, or intratumoral androgen biosynthesis, the clinical response has been to find better ways to suppress it. Oestrogen in this context has been a peripheral consideration: present in men, acknowledged to affect the prostate, and then set aside.

This peripheral status is not well-justified by the evidence. The prostate is an oestrogen-responsive tissue. It expresses two distinct oestrogen receptors with opposing functional profiles. It contains the enzymatic machinery to produce oestrogen locally from androgen precursors. Its cells are exposed to recirculating oestrogen whose levels are governed in part by gut microbial metabolism. And in men living in industrialised environments, those cells are additionally exposed to a continuous low-level background of synthetic oestrogen-mimicking compounds whose prostate-specific effects have barely been examined.

The breast cancer field went through an extended period of oestrogen overclaiming, attributing to oestrogen a dominance in pathogenesis that subsequent research qualified and contextualised. That correction has sometimes been misread as a demotion of oestrogen’s importance. The lessons from breast cancer are more nuanced: oestrogen matters, its effects are receptor-subtype specific, local and systemic levels may diverge substantially, and the microenvironmental and exogenous oestrogen load is relevant in ways that have only recently been tractable to measure.

This paper applies those lessons to prostate cancer. It does not argue that prostate cancer is an oestrogen-driven disease in the way that ER-positive breast cancer is. It argues that oestrogen operates through at least four distinct mechanisms that contribute to disease initiation, progression, invasion, and resistance, and that those mechanisms have been individually described in the literature, rarely integrated, and almost never translated into clinical thinking.

The paper is organised around four mechanisms: the ERα/ERβ receptor balance; intratumoral aromatase and locally synthesised oestrogen; the estrobolome and systemic oestrogen recirculation; and xenoestrogen loading and AR interaction. The TMPRSS2:ERG gene fusion, present in approximately half of all prostate cancers, is examined as a specific molecular intersection between oestrogen signalling and the most common genomic alteration in the disease. The framing throughout is hypothesis-generating. The mechanisms described are supported by published evidence; the integrated framework proposed here has not been formally tested.

02Mechanism One, The ERα/ERβ Balance and Its Progressive Remodelling

2.1 The Two Receptors and Their Opposing Functions

The human prostate expresses both ERα (ESR1) and ERβ (ESR2), but their functions are not symmetrical and their expression patterns diverge during carcinogenesis. ERβ is the dominant receptor in normal prostate epithelium and is generally considered tumour-suppressive.^[1]

Its ligand in the prostate is not primarily estradiol but 5α-androstane-3β,17β-diol (3β-adiol), a non-androgenic metabolite of dihydrotestosterone that binds ERβ with high affinity and does not activate AR. Through ERβ, 3β-adiol maintains epithelial differentiation, restrains proliferation, and suppresses the mesenchymal transition programme.^[2]

ERα has the opposite functional profile in this tissue. Where ERβ suppresses, ERα promotes, proliferative signalling, inflammatory cytokine induction, and the transcriptional programmes associated with invasion. ERα is expressed at low levels in normal prostate epithelium and at higher levels in stromal cells; its pattern shifts during malignant transformation, with increased epithelial expression emerging as disease advances.^[1][3]

2.2 ERβ Loss and Gleason Grade

The relationship between ERβ expression and disease grade is one of the more consistent findings in the oestrogen-prostate cancer literature. ERβ expression decreases progressively with increasing Gleason grade, and its loss correlates with higher metastatic potential.^[3]

The mechanistic explanation for this relationship has been clarified: ERβ destabilises HIF-1α and transcriptionally represses VEGF-A. When ERβ is lost, HIF-1α accumulates, VEGF-A rises, and the VEGF receptor neuropilin-1 drives Snail1 nuclear localisation, the transcriptional event that executes epithelial-mesenchymal transition.^[2]

The implication is that ERβ loss is not merely a marker of high-grade disease but a functional contributor to it. The loss of ERβ removes a brake on HIF-1α-mediated hypoxia adaptation and EMT, creating conditions that are more permissive to invasion. This is not an association, it is a mechanism, and it has been demonstrated at the molecular level in human prostate cancer tissue.^[2][3]

2.3 The Progression Trajectory

The ERα/ERβ balance undergoes a structured remodelling during prostate cancer development and progression. In high-grade prostatic intraepithelial neoplasia (HGPIN), the recognised precursor lesion, ERα is upregulated and ERβ is partially lost. ERβ is generally retained in hormone-naïve prostate cancer but progressively lost in castration-resistant disease. At the castration-resistant stage, ERα and the oestrogen-regulated progesterone receptor both emerge as features of the tumour transcriptome, suggesting that CRPC tumours can use oestrogens and progestins for their growth.^[1]

This progression narrative has a direct clinical implication that has not been acted on. If ERβ is tumour-suppressive and its loss enables EMT and disease progression, then ERβ agonism is a potential intervention point, particularly in the surveillance or post-treatment recurrence-risk setting, before ERβ expression has been fully lost.

ERβ-specific agonists have been developed and tested in cell line models with promising results. Clinical investigation in prostate cancer has been limited.^[4]

2.4 ERα as a Therapeutic Target

Preliminary clinical studies with the ERα antagonist toremifene have identified ERα as a candidate target for prostate cancer prevention, particularly in men with HGPIN. ERα antagonism in this setting addresses the carcinogenic effects of estradiol signalling through ERα at the precursor lesion stage, precisely where the imbalance begins and where intervention might prevent the transition to invasive disease.^[1]

The broader implication is that the oestrogen receptor system in prostate cancer presents two potential intervention points operating in opposite directions: ERβ agonism to restore tumour suppression, and ERα antagonism to block proliferative signalling. Neither has been integrated into prostate cancer management despite mechanistic support and preliminary clinical signal.

03Mechanism Two, Intratumoral Aromatase and Locally Generated Oestrogen

3.1 Aromatase Expression Switches in Malignancy

Aromatase, the CYP19A1 enzyme that converts androgens to oestrogens, has a defined distribution in normal and malignant prostate tissue. In nonmalignant prostate tissue, aromatase mRNA expression is absent from epithelium and localised to stromal cells. Aromatase protein is present in stroma and is driven by promoter PII. This stromal expression generates a local oestrogen environment that acts on adjacent epithelial cells in a paracrine fashion.^[5]

In malignant tissue, the distribution changes. Aromatase was expressed and active in epithelial tumour cells in laser-capture microdissection studies of prostate cancer tissue, benign prostate epithelial cells showed no expression or activity. The switch from stromal-only to epithelial expression in malignancy means the tumour cell itself begins producing oestrogen locally. This is an intracrine oestrogen source, independent of systemic circulating levels and potentially generating tissue oestrogen concentrations that diverge substantially from what serum measurements would suggest.^[5]

3.2 Aromatase in Castration-Resistant Disease and Cancer Stem Cells

CYP19A1 expression is significantly higher in CRPC tissues and cell lines than in primary prostate cancer. Patients with higher CYP19A1 expression in CRPC suffered poorer overall survival after first hormone therapy. The trajectory, low aromatase in benign tissue, increased in primary cancer, further increased in CRPC, parallels exactly the progression trajectory of ERβ loss: as androgen suppression reshapes the hormonal environment, oestrogen production by the tumour itself becomes more prominent.^[6]

Most striking is the cell-specific distribution within the tumour. In several prostate cancer cell lines, aromatase was predominantly expressed in the CD44+ subset, the cancer stem cell fraction. This concentration of aromatase in CSCs creates a self-sustaining oestrogen niche within the most treatment-resistant subpopulation of the tumour.^[6]

3.3 The ERα, MMP12 Invasion Circuit

The functional consequence of intratumoral aromatase in CRPC has been characterised at the molecular level. Increased endogenous oestrogen catalysed by elevated aromatase enhances MMP12 expression via ERα, oestrogen binds ERα, which binds the MMP12 promoter oestrogen response element and drives transcription. MMP12 (macrophage metalloelastase) degrades elastin and other extracellular matrix components, facilitating tumour invasion and metastatic spread.^[6]

The circuit is therefore: ADT → reduced androgen → upregulated intratumoral aromatase (particularly in CSCs) → increased local oestrogen → ERα activation → MMP12 upregulation → enhanced invasion. This is a specific, mechanistically defined pathway by which androgen deprivation therapy may inadvertently promote invasive behaviour in CRPC through the oestrogen axis, a pathway that has received almost no clinical attention.

3.4 Aromatase as a Therapeutic Target

Aromatase inhibitors, letrozole, anastrozole, exemestane, have been examined in CRPC. Phase II data with letrozole in CRPC did not demonstrate significant benefit in unselected patients. However, these trials were conducted before the CSC-specific aromatase expression pattern was characterised and before the ERα-MMP12 invasion circuit was defined. The relevant patient selection question, whether patients with high tumour aromatase expression or CD44+ CSC enrichment show differential benefit, has not been asked in a clinical trial context.^[7]

04Mechanism Three, The Estrobolome and Systemic Oestrogen Recirculation

4.1 How the Estrobolome Works

Oestrogens processed in the liver are conjugated, typically glucuronidated, to render them water-soluble and facilitate their excretion via bile into the intestinal lumen. A proportion of this conjugated oestrogen is acted upon by bacterial β-glucuronidase enzymes that cleave the glucuronide, releasing unconjugated, biologically active, oestrogen that can then be reabsorbed across the intestinal wall into portal circulation. This enterohepatic recirculation of oestrogen is a normal physiological process. The estrobolome is the collective term for the gut microbial genes and taxa responsible for this activity.^[8]

The genera most consistently involved include Clostridium, Bacteroides, Eubacterium, Lactobacillus, and Ruminococcus, all of which carry β-glucuronidase encoding genes. When the microbiome is dysbiotic, reduced in diversity, shifted toward pro-inflammatory taxa, β-glucuronidase activity can increase, driving elevated reabsorption and higher circulating free oestrogen.^[9]

4.2 Relevance to Prostate Cancer

The estrobolome literature has developed primarily in the breast cancer context, where elevated circulating oestrogen has a well-established causal role. Its application to prostate cancer is acknowledged but has not attracted comparable research investment. The mechanistic argument for relevance is identical: elevated free circulating oestrogen driven by excess β-glucuronidase activity would increase the systemic oestrogen load to which prostate cells are exposed, activating ERα signalling with the proliferative and inflammatory consequences described above.^[10]

An elevated estradiol/testosterone ratio has been identified as a significant factor in prostate cancer pathogenesis. Obesity, which increases aromatase activity in adipose tissue and suppresses sex-hormone binding globulin, contributes to this ratio by raising the oestrogen component relative to testosterone. Gut dysbiosis, which simultaneously increases β-glucuronidase-mediated oestrogen reabsorption, would compound this effect.^[10]

4.3 The Phytoestrogen Complexity

Phytoestrogens, dietary compounds with oestrogenic activity, particularly isoflavones from soy and lignans from flaxseed, are also substrates of the gut microbiome. Specific gut bacteria convert daidzein to equol, a metabolite with higher binding affinity for ERβ than its precursor and with demonstrable anti-androgenic and cancer-suppressive properties in cell models. The ability to produce equol varies substantially across populations and individuals, depending on the presence of specific gut microbial taxa, not all individuals exposed to the same dietary phytoestrogen load produce equol.^[11]

This variability may partially explain epidemiological observations about dietary phytoestrogen and prostate cancer risk, which have been inconsistent across populations. If the relevant outcome is not isoflavone exposure but equol production, and equol production depends on microbiome composition, then population-level dietary studies will show inconsistent results unless microbiome composition is measured and stratified.

05Mechanism Four, Xenoestrogen Loading and Androgen Receptor Interaction

5.1 The Xenoestrogen Landscape

Xenoestrogens are synthetic compounds that interact with oestrogen receptors or mimic oestrogen function. The most clinically studied in the prostate cancer context is bisphenol A (BPA), a plasticiser present in polycarbonate plastics and epoxy resins with near-universal human exposure in industrialised populations. BPA is accompanied by phthalates, parabens, polychlorinated biphenyls, organochlorine pesticides, and a range of other compounds with oestrogenic or anti-androgenic activity.^[12]

The ’cocktail mixture effect’, the combined oestrogenic activity of multiple low-dose exposures that are individually below regulatory thresholds, has been described, with biological impacts at concentrations substantially below current regulatory limits. For the prostate cancer context, the relevant question is not whether any single compound causes cancer but whether the cumulative xenoestrogen load alters the hormonal environment in ways that contribute to initiation, progression, or resistance over the decades-long timeline of the disease.^[12]

5.2 BPA and Androgen Receptor Activation

The connection between xenoestrogens and prostate cancer does not run exclusively through oestrogen receptors. BPA at low, environmentally relevant doses enhances the transcriptional efficacy of the androgen receptor in prostate cancer cells. It also activates multiple tumour-derived mutant AR alleles and moderately induces wild-type AR activity. This is a different mechanism from ER binding, it represents a xenoestrogen directly potentiating the primary driver of prostate cancer progression and resistance.^[13]

The clinical significance is considerable. The development of castration-resistant prostate cancer is driven largely by AR reactivation, through AR amplification, AR mutation, AR splice variants (particularly AR-V7), and intratumoral androgen biosynthesis. BPA’s capacity to activate mutant AR alleles and enhance AR transcriptional activity means that environmental xenoestrogen exposure may be augmenting the same molecular mechanisms that cause ADT to fail.

5.3 Developmental Exposure and Epigenetic Programming

Developmental exposure to BPA increases prostate cancer susceptibility in adult rats through an epigenetic mode of action. Perinatal BPA exposure induces angiogenic ER signalling and activates the PI3K/AKT pathway, with epigenome reprogramming occurring via AKT phosphorylation and EZH2 inactivation, a histone methyltransferase whose activity shapes long-term gene expression patterns.^[12][14]

5.4 Metabolic Pathway Effects

Beyond ER and AR interactions, some xenoestrogens promote the 16-hydroxy estrone metabolic pathway over the 2-hydroxy estrone pathway. 16-hydroxy estrone is more genotoxic than 2-hydroxy estrone, it has DNA-damaging properties and is present at elevated concentrations in breast cancer tissues. Compounds including DDT, DDE, atrazine, and specific phthalates push oestrogen metabolism toward the more damaging metabolite.^[12]

06The TMPRSS2:ERG Fusion, Oestrogen’s Most Clinically Significant Intersection

The TMPRSS2:ERG gene fusion is the most common somatic alteration in prostate cancer, present in approximately 50% of cases. The fusion places the ERG oncogene under the transcriptional control of the TMPRSS2 promoter, an androgen-regulated element. The result is androgen-driven overexpression of ERG, a transcription factor that promotes invasion, EMT, and multiple oncogenic programmes.^[15]

The fusion is a relatively early event in carcinogenesis, detectable in HGPIN, and associated with lethal disease in watchful waiting cohorts.^[16]

The androgen-regulation of this fusion is well-established. What is substantially less discussed is the oestrogen regulation of the same fusion. ERα agonism increases TMPRSS2:ERG expression; ERβ agonism decreases it. Estrogen-dependent signalling has been identified in a molecularly distinct, more aggressive subclass of prostate cancer in which the TMPRSS2:ERG fusion is expressed.^[1][17]

The clinical implications of this are material. In the approximately 50% of prostate cancer patients whose tumours carry the TMPRSS2:ERG fusion, oestrogen signalling through ERα is a co-driver of the oncogenic programme. Androgen deprivation alone removes one regulatory input but leaves the other intact, and, as described in the aromatase section, ADT may simultaneously increase intratumoral oestrogen production through CYP19A1 upregulation, potentially compensating at the oestrogen input node for what was suppressed at the androgen node.

ERβ agonism presents a specific hypothesis in this population: if ERβ activation downregulates TMPRSS2:ERG expression while simultaneously suppressing EMT and restoring epithelial differentiation, then ERβ-selective agonism in TMPRSS2:ERG-positive patients represents a mechanistically targeted approach that addresses the oestrogen dimension of the fusion gene’s regulation. This hypothesis has cell-line support and constitutes a testable clinical question.^[4]

07Convergence and the Quiet Biology Framework

The four mechanisms described do not operate independently. They form an interconnected system in which oestrogen exposure, oestrogen receptor balance, local oestrogen production, and the molecular consequences of oestrogen signalling interact across multiple timescales and tissue compartments.

The estrobolome sets the systemic oestrogen background, the recirculating free oestrogen load to which prostate cells are chronically exposed. Xenoestrogens add to and disturb this background, while simultaneously activating AR through non-ER mechanisms. Intratumoral aromatase generates local oestrogen that diverges from systemic levels, concentrated in the cancer stem cell fraction and driving ERα-dependent MMP12 in CRPC. The ERα/ERβ balance determines how all of this oestrogen, local and systemic, is transduced into cellular behaviour, with the progressive loss of tumour-suppressive ERβ as disease advances removing the biological counterweight to ERα-driven oncogenic signalling.

The TMPRSS2:ERG fusion sits at the intersection of this system and the androgen system, regulated by both. Its behaviour under ADT, where androgen input is suppressed but oestrogen input may simultaneously be increasing through intratumoral aromatase upregulation, illustrates precisely why managing only one steroid hormone system in a disease regulated by both produces incomplete and eventually failing responses.

The Quiet Biology framework addresses prostate cancer as a conditionally maintained adaptive system. The oestrogen mechanisms described in this paper are, in that framing, upstream conditions sustaining tumour behaviour that the androgen-focused clinical model does not address. The ERβ loss permitting EMT, the aromatase-driven CSC oestrogen niche, the dysbiotic estrobolome elevating free oestrogen systemically, the xenoestrogen background activating AR, none of these is addressed by androgen deprivation, radiation, or the metabolic and mitochondrial interventions described elsewhere in this series. They represent a distinct ecological dimension of the disease that has been largely invisible because the clinical frame has not looked for it.

08Limitations and Honest Boundaries

This paper synthesises four mechanistic domains that have been individually described but not previously integrated. The synthesis is hypothesis-generating, not confirmatory. Several qualifications matter.

The ERα/ERβ receptor biology is well-established and replicated. The mechanistic link between ERβ loss and EMT has been demonstrated at the molecular level. The progression trajectory is supported by multiple independent cohorts. This is the strongest pillar in the paper.

The intratumoral aromatase findings, the epithelial expression switch in malignancy and the CSC concentration in CRPC, are from published primary studies with appropriate methods. The ERα-MMP12 circuit has been characterised mechanistically. The failure of aromatase inhibitor trials in unselected CRPC patients does not invalidate this mechanism; it may reflect the absence of patient selection by aromatase expression or CSC phenotype, which was not attempted in those trials.

The estrobolome literature is well-developed in breast cancer. Its application to prostate cancer is acknowledged in the literature but has not been examined with comparable rigour. The mechanistic argument for relevance is strong; the prostate-specific evidence base is thin. This pillar is the most inferential of the four.

The xenoestrogen literature is large but heterogeneous. The specific BPA/AR activation data are from cell line studies at concentrations that overlap with environmental exposure levels; in vivo confirmation in humans is more limited. The developmental exposure/epigenetic programming data are from animal models. Extrapolation to human prostate cancer risk requires caution.

The TMPRSS2:ERG/oestrogen connection is supported by the published literature but the clinical question, whether ERβ agonism in TMPRSS2:ERG-positive patients produces measurable benefit, has not been tested in a clinical trial. It is a testable hypothesis, not a demonstrated effect.

09Conclusions

Oestrogen is not a bystander hormone in prostate cancer. It operates through at least four mechanistically distinct pathways, receptor imbalance,^[1,2,3,4] intratumoral aromatase,^[5,6,7] estrobolome dysbiosis,^[8,9,10,11] and xenoestrogen loading^[12,13,14], that collectively contribute to initiation, EMT, invasion, stem cell maintenance, resistance to androgen deprivation, and the expression of the most common molecular subtype of the disease.

The TMPRSS2:ERG gene fusion,^[15,16,17] present in approximately half of all prostate cancers, is regulated by both androgen and oestrogen signalling. In a patient whose tumour carries this fusion and who is on androgen deprivation therapy, oestrogen represents an unaddressed co-driver of the same oncogenic programme that ADT is attempting to suppress. The possibility that ADT increases intratumoral aromatase activity and thus oestrogen input to the fusion gene as androgen input is withdrawn^[6] deserves formal investigation.

The integrated framework proposed here has not been tested as a whole. Each mechanism has a published evidence base; the framework connecting them is the contribution of this paper. The clinical implications, ERβ agonism in HGPIN or localised disease, aromatase inhibition selected by tumour aromatase expression in CRPC, estrobolome characterisation as a stratifier for systemic oestrogen load, xenoestrogen reduction as a modifiable environmental risk factor, represent a research agenda rather than established practice.

Oestrogen is not a bystander hormone in prostate cancer.

It has been operating throughout, in the receptor landscape, in the tumour, in the gut, and in the environment.

References

1. 01Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol. 2009;55(3):533-542.
2. 02Maggiolini M, et al. ERβ impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated Snail nuclear localization: implications for Gleason grading. PubMed PMID: 20385358. 2010.
3. 03Tong JS, et al. Expression of oestrogen receptor-alpha and oestrogen receptor-beta in prostate cancer. PMID: 17908481. 2007. ERβ decrease associated with higher Gleason grade and metastatic potential.
4. 04Hoffmann M, et al. Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer. PMID: 28380417. 2017. ERβ agonist 8β-VE2 reduces AR and AR splice variant overexpression under maximal ADT.
5. 05Ellem SJ, Risbridger GP. Local aromatase expression in human prostate is altered in malignancy. PubMed PMID: 15126575. 2004. Aromatase switches from stromal-only in benign tissue to epithelial expression in tumour cells.
6. 06Ye L, et al. Aromatase-induced endogenous estrogen promotes tumour metastasis through ERα/MMP12 axis activation in castration-resistant prostate cancer. Cancer Lett. 2019. Aromatase concentrated in CD44+ CSC fraction; CYP19A1 higher in CRPC; lethal in patients with high expression.
7. 07Smith MR, et al. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma: a phase II study of letrozole. Cancer. 2002;95:1864-1868.
8. 08Plottel CS, Blaser MJ. Microbiome and malignancy. Cell Host Microbe. 2011;10:324-335. Estrobolome concept and β-glucuronidase mechanism.
9. 09Baker JM, et al. Estrogen-gut microbiome axis: physiological and clinical implications. PMID: 28778332. 2017. Enterohepatic recirculation and estrobolome regulation.
10. 10Dobbs RW, et al. Estrogens and prostate cancer. Prostate Cancer Prostatic Dis. 2019;22:185-194. Elevated estradiol/testosterone ratio in prostate cancer pathogenesis; obesity and aromatase.
11. 11Larnder A, et al. The estrobolome: estrogen-metabolising pathways of the gut microbiome and their relation to breast cancer. Int J Cancer. 2025. Equol production and microbiome-dependent phytoestrogen metabolism.
12. 12Gachowska M, et al. The influence of environmental exposure to xenoestrogens on the risk of cancer development. Int J Mol Sci. 2024;25(22):12363. Comprehensive review of BPA, phthalates, DDT, 16-OH estrone pathway.
13. 13Wetherill YB, et al. Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther. 2006. BPA activates mutant AR alleles at environmentally relevant doses.
14. 14Prins GS, et al. Developmental exposure to bisphenol A increases prostate cancer susceptibility in adult rats: epigenetic mode of action is implicated. Fertil Steril. 2008;89(Suppl 1):41-42.
15. 15Tomlins SA, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648.
16. 16Demichelis F, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-4599.
17. 17Setlur SR, et al. Estrogen-dependent signalling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100(11):815-825.
18. 18McGrath S, et al. Etiology of prostate cancer with the TMPRSS2:ERG fusion: a systematic review of risk factors. Int J Cancer. 2025.
19. 19Mishra S, et al. Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer. Oncotarget. 2015;6:44388-44402.
20. 20Black A, et al. Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2374-2382.